<DOC>
	<DOCNO>NCT00688896</DOCNO>
	<brief_summary>The purpose study evaluate effect two dose level JTT-705 co-administered pravastatin 40 mg HDL-C LDL-C inhibition rate CETP activity document short term safety .</brief_summary>
	<brief_title>Efficacy Safety Study JTT-705 Combination With Pravastatin 40 mg Patients With Type II Hyperlipidemia</brief_title>
	<detailed_description />
	<mesh_term>Hyperlipidemias</mesh_term>
	<mesh_term>Hyperlipoproteinemia Type II</mesh_term>
	<mesh_term>Pravastatin</mesh_term>
	<mesh_term>Dalcetrapib</mesh_term>
	<criteria>Patients lipid value indicate : HDLC le 1.6 mmol/L ( 60 mg/dL ) TG le 4.5 mmol/L ( 400 mg/dL ) LDL 4.0 mmol/L ( 160 mg/dL ) Patients CHD CHD risk equivalent Male females 18 65 year age ( female patient must postmenopausal , surgically sterile use acceptable form contraception ) Body Mass Index â‰¥ 35 kg/m2 Females pregnant breastfeeding , females child bear potential use effective method contraception Concomitant use medication identify protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2008</verification_date>
</DOC>